HIV Drugs Market Size is valued at 39.29 Billion in 2024 and is predicted to reach 59.74 Billion by the year 2034 at a 4.4% CAGR during the forecast period for 2025-2034.
Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). The virus damages the immune system and thus interferes with the body’s ability to fight organisms that cause disease. HIV attacks immune cells, specifically CD-4 cells, and makes the body susceptible to infections and other diseases.
AIDS is a life-threatening and chronic disease that can be transmitted from one person to another through various routes, including sexual intercourse, direct injection with HIV-contaminated drugs, needles, syringes, blood or blood products, and from HIV-infected mothers to fetuses. As of now, no cure for AIDS. However, antiretroviral regimens (ARVs) are recommended for patients with HIV as it can dramatically slow the disease progression as well as prevent other infections and complications.
The increasing prevalence of HIV/AIDS worldwide catalyzes the growth of the global HIV drugs market. According to UNAIDS, in 2019, the total number of patients with HIV/AIDS was around 38 million across the globe. The adult and children population was 36.2 and 1.8 million, respectively.
Additionally, several initiatives are undertaken by governments/associations/organizations in respective countries and globally to educate and raise awareness, availability of generic HIV drugs, and new drug development and regulatory approvals for HIV treatment are expected to drive the market further. For instance, in March 2020, ViiV Healthcare, the subsidiary of GlaxoSmithKline, received regulatory approval for its long-acting regimen for the treatment of HIV; CABENUVA by Health Canada.
The Global HIV drugs market is segmented on the basis of drug type and distribution channel. By Drug Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry and Fusion Inhibitors, Combination Class Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market in 2024, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 39.29 Billion |
|
Revenue Forecast In 2034 |
USD 59.74 Billion |
|
Growth Rate CAGR |
CAGR of 4.4% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug type and Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Gilead Sciences, ViiV Healthcare, Janssen, Merck & Co., Bristol-Myers Squibb, TaiMed Biologics, CytoDyn, Boehringer Ingelheim International GmbH, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan among others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV Drugs Market Snapshot
Chapter 4. Global HIV Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Clinical Trial/Pipeline Analysis
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Clinical Trial Analysis 2019
4.7. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: Drug Type Estimates & Trend Analysis
5.1. Drug Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.2.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.3. Protease Inhibitors (PIs)
5.2.4. Integrase Inhibitors
5.2.5. Entry and Fusion Inhibitors
5.2.6. Combination Class Drugs
Chapter 6. Market Segmentation 2: Distribution Channel Estimates & Trend Analysis
6.1. Distribution Channel & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
Chapter 6. HIV Drugs Market Segmentation 3: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by drug type, 2021 to 2034
6.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by distribution channel, 2021 to 2034
6.1.2. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by country, 20
6.1.2.1. U.S.
6.1.2.2. Canada
6.2. Europe
6.2.1. Europe HIV Drugs Market revenue (US$ Million) by drug type, 2021 to 2034
6.2.1. Europe HIV Drugs Market revenue (US$ Million) by distribution channel, 2021 to 2034
6.2.2. Europe HIV Drugs Market revenue (US$ Million) by country, 2021 to 2034
6.2.2.1. Germany
6.2.2.2. Poland
6.2.2.3. France
6.2.2.4. Italy
6.2.2.5. Spain
6.2.2.6. UK
6.2.2.7. Rest of Europe
6.3. Asia Pacific
6.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by drug type, 2021 to 2034
6.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by distribution channel, 2021 to 2034
6.3.2. Asia Pacific HIV Drugs Market revenue (US$ Million) by country, 2021 to 2034
6.3.2.1. China
6.3.2.2. India
6.3.2.3. Japan
6.3.2.4. Australia
6.3.2.5. Rest of Asia Pacific
6.4. Latin America
6.4.1. Latin America HIV Drugs Market revenue (US$ Million) by drug type, (US$ Million) 2021 to 2034
6.4.1. Latin America HIV Drugs Market revenue (US$ Million) by distribution channel, (US$ Million) 2021 to 2034
6.4.2. Latin America HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2021 to 2034
6.4.2.1. Brazil
6.4.2.2. Rest of Latin America
6.5. MEA
6.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by drug type, (US$ Million) 2021 to 2034
6.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by distribution channel, (US$ Million) 2021 to 2034
6.5.2. MEA revenue HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2021 to 2034
6.5.2.1. South Africa
6.5.2.2. Rest of MEA
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Gilead Sciences
7.2.2. ViiV Healthcare
7.2.3. Janssen
7.2.4. Bristol-Myers Squibb
7.2.5. TaiMed Biologics
7.2.6. CytoDyn
7.2.7. Boehringer Ingelheim International GmbH
7.2.8. Merck & Co. Inc.
7.2.9. AbbVie
7.2.10. F. Hoffmann-La Roche Ltd.
7.2.11. Teva Pharmaceutical Industries Ltd.
7.2.12. Cipla Limited
7.2.13. Daiichi Sankyo
7.2.14. Emcure
7.2.15. Hetero Drugs
7.2.16. Mylan
7.2.17. Shantou Huatai Pharmaceutical Co., Ltd.
7.2.18. Shengzhen Chongway Biotechnology Co., Ltd.
7.2.19. Other Prominent Player
Global HIV Drugs Market By Drug Type
Global HIV Drugs Market By Distribution Channel
Global HIV Drugs Market Revenue (US$ Mn), By Region,
North America HIV Drugs Market Revenue (US$ Mn), by Country,
Europe HIV Drugs Market Market Revenue (US$ Mn), by Country,
Asia Pacific HIV Drugs Market Revenue (US$ Mn), by Country,
Latin America HIV Drugs Market Revenue (US$ Mn), by Country,
Middle East & Africa HIV Drugs Market Revenue (US$ Mn), by Country,
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
